# Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

> **NCT01403610** · PHASE2 · COMPLETED · sponsor: **The University of Texas Health Science Center at San Antonio** · enrollment: 28 (actual)

## Conditions studied

- HIGH GRADE GLIOMA

## Interventions

- **DRUG:** TH-302 preoperative
- **DRUG:** Placebo
- **DRUG:** TH-302 (escalating) with bevacizumab 10mg/kg

## Key facts

- **NCT ID:** NCT01403610
- **Lead sponsor:** The University of Texas Health Science Center at San Antonio
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2019-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01403610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01403610, "Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01403610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*